AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics
Another first for validated Morphomer® discovery technology platform in developing small molecules able to selectively target pathological human proteins
LAUSANNE,
Over 200 participants from the investment and biopharmaceutical industries participated in the live event featuring presentations from Dr.
Dr.
Prof.
During the Webinar,
- ACI-12589 shows a rapid brain uptake and fast signal equilibrium
- Standardized Uptake Value Ratio (SUVR) can be used with occipital or cerebellar grey reference region
- Strong binding in expected regions in MSA and complete separation of MSA from other a-synucleinopathies and controls
- ACI-12589 is a promising PET tracer supporting a diagnosis of MSA and a-synuclein drug target engagement
In addition to diagnostic candidates, like ACI-12589, the
ACI-12589 is derived from AC Immune’s clinically validated Morphomer® technology platform, which accelerates the design, development and synthesis of conformation-specific, brain penetrant small molecules ideal for use in CNS indications. The Morphomer® platform has generated significant revenues for
About
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of
For further information, please contact:
Media Relations Phone: +41 21 345 91 34 Email:saoyuth.nidh@acimmune.com |
Investor Relations Phone: +41 21 345 91 91 Email:gary.waanders@acimmune.com |
LaVoieHealthScience Phone: +1 609 516 5761 Email:slewis@lavoiehealthscience.com |
U.S. Investors Phone: +1 212 915 2577 Email:cdavis@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA